---
layout: default
title: Riluzole
description: "Riluzole çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 148
evidence_level: L4
indication_count: 10
---

# Riluzole

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Riluzoleï¼šå¾ ALS åˆ°é‹å‹•ç¥ç¶“å…ƒç›¸é—œç–¾ç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Riluzole å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Riluzole æ˜¯ä¸€ç¨®è°·æ°¨é…¸æ‹®æŠ—åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼è‚Œèç¸®è„Šé«“å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰çš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°å¤šç¨®é‹å‹•ç¥ç¶“å…ƒç›¸é—œç–¾ç—…æœ‰æ•ˆï¼ŒåŒ…æ‹¬**ä¸‹é‹å‹•ç¥ç¶“å…ƒç—‡å€™ç¾¤ (Lower Motor Neuron Syndrome)** å’Œ **ALS æ˜“æ„Ÿæ€§**ï¼Œç›®å‰æœ‰ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è‚Œèç¸®è„Šé«“å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bilateral parasagittal parieto-occipital polymicrogyriaã€amyotrophic lateral sclerosisã€axial spondylometaphyseal dysplasiaã€lower motor neuron syndrome with late-adult onsetã€trichomegaly-retina pigmentary degeneration-dwarfism syndromeã€lethal arthrogryposis-anterior horn cell disease syndromeã€monomelic amyotrophyã€Mills syndromeã€amyotrophic lateral sclerosis, susceptibility toã€autosomal dominant mitochondrial myopathy with exercise intolerance |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.94%-99.98% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. bilateral parasagittal parieto-occipital polymicrogyria</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Riluzole æ˜¯ç›®å‰å”¯ä¸€è¢«æ ¸å‡†ç”¨æ–¼ ALS æ²»ç™‚çš„è—¥ç‰©ã€‚å®ƒçš„ä¸»è¦ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š</p>
<ul>
<li>æŠ‘åˆ¶è°·æ°¨é…¸é‡‹æ”¾</li>
<li>é˜»æ–·é›»å£“ä¾è³´æ€§éˆ‰é›¢å­é€šé“</li>
<li>æ¸›å°‘èˆˆå¥®æ€§æ¯’æ€§ï¼ˆexcitotoxicityï¼‰</li>

</ul>
<p>ALS çš„ç‰¹å¾µæ˜¯ä¸Šä¸‹é‹å‹•ç¥ç¶“å…ƒçš„é€²è¡Œæ€§é€€åŒ–ã€‚TxGNN é æ¸¬çš„å¹¾å€‹é©æ‡‰ç—‡èˆ‡ ALS åœ¨ç—…ç†æ©Ÿè½‰ä¸Šæœ‰å¯†åˆ‡é—œè¯ï¼š</p>

<ol>
<li><strong>ä¸‹é‹å‹•ç¥ç¶“å…ƒç—‡å€™ç¾¤ï¼ˆæ™šç™¼å‹ï¼‰</strong>ï¼šèˆ‡ ALS å…±äº«ä¸‹é‹å‹•ç¥ç¶“å…ƒé€€åŒ–çš„ç‰¹å¾µ</li>
<li><strong>Mills ç—‡å€™ç¾¤</strong>ï¼šä¸€ç¨®ä»¥å–®å´é€²è¡Œæ€§è‚¢é«”ç„¡åŠ›ç‚ºç‰¹å¾µçš„é‹å‹•ç¥ç¶“å…ƒç–¾ç—…</li>
<li><strong>ALS æ˜“æ„Ÿæ€§</strong>ï¼šä»£è¡¨å¯èƒ½ç™¼å±•ç‚º ALS çš„é«˜é¢¨éšªç‹€æ…‹</li>
<li><strong>å–®è‚¢è‚Œèç¸®ç—‡ï¼ˆMonomelic Amyotrophyï¼‰</strong>ï¼šä¸€ç¨®å±€é™æ€§çš„é‹å‹•ç¥ç¶“å…ƒç–¾ç—…</li>

</ol>
<p>é€™äº›ç–¾ç—…éƒ½æ¶‰åŠé‹å‹•ç¥ç¶“å…ƒçš„é€€åŒ–ï¼Œriluzole çš„ç¥ç¶“ä¿è­·ä½œç”¨å¯èƒ½å°é€™äº›ç–¾ç—…æœ‰é¡ä¼¼çš„ç™‚æ•ˆã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. axial spondylometaphyseal dysplasia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. lower motor neuron syndrome with late-adult onset</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. trichomegaly-retina pigmentary degeneration-dwarfism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. lethal arthrogryposis-anterior horn cell disease syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. monomelic amyotrophy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Mills syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. amyotrophic lateral sclerosis, susceptibility to</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9178165/" target="_blank">9178165</a></td><td>1997</td><td>Article</td><td>Journal of neurology</td><td>Glutamate, excitotoxicity and amyotrophic lateral sclerosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16723044/" target="_blank">16723044</a></td><td>2006</td><td>Article</td><td>Expert reviews in molecular me</td><td>Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21128691/" target="_blank">21128691</a></td><td>2011</td><td>Article</td><td>CNS drugs</td><td>Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22763933/" target="_blank">22763933</a></td><td>2012</td><td>Article</td><td>Praxis</td><td>[Amyotrophic lateral sclerosis--diagnosis and treatment].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20942786/" target="_blank">20942786</a></td><td>2010</td><td>Article</td><td>CNS &amp; neurological disorders d</td><td>Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39217293/" target="_blank">39217293</a></td><td>2024</td><td>Article</td><td>BMC neurology</td><td>Multiple sclerosis and amyotrophic lateral sclerosis: is there an association or...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20942785/" target="_blank">20942785</a></td><td>2010</td><td>Article</td><td>CNS &amp; neurological disorders d</td><td>Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19593125/" target="_blank">19593125</a></td><td>2009</td><td>Article</td><td>Current opinion in neurology</td><td>Recent advances in motor neuron disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17389297/" target="_blank">17389297</a></td><td>2007</td><td>Article</td><td>Neurology</td><td>Amyotrophic lateral sclerosis: a global threat with a possible difference in ris...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22646982/" target="_blank">22646982</a></td><td>2011</td><td>Article</td><td>Expert opinion on drug discove</td><td>The preclinical discovery of amyotrophic lateral sclerosis drugs.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20698807/" target="_blank">20698807</a></td><td>2011</td><td>Article</td><td>Amyotrophic lateral sclerosis </td><td>The epidemiology and treatment of ALS: focus on the heterogeneity of the disease...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37565261/" target="_blank">37565261</a></td><td>2023</td><td>Article</td><td>European journal of translatio</td><td>Proteomic profiling of the brain from the wobbler mouse model of amyotrophic lat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18045911/" target="_blank">18045911</a></td><td>2007</td><td>Article</td><td>The Journal of neuroscience : </td><td>Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30089514/" target="_blank">30089514</a></td><td>2018</td><td>Article</td><td>Molecular neurodegeneration</td><td>Joint genome-wide association study of progressive supranuclear palsy identifies...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40672281/" target="_blank">40672281</a></td><td>2025</td><td>Article</td><td>bioRxiv : the preprint server </td><td>Human TDP-43 overexpression in zebrafish motor neurons triggers MND-like phenoty...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24862874/" target="_blank">24862874</a></td><td>2014</td><td>Article</td><td>Amyotrophic lateral sclerosis </td><td>Evidence of an environmental effect on survival in ALS.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41280004/" target="_blank">41280004</a></td><td>2025</td><td>Article</td><td>bioRxiv : the preprint server </td><td>Riluzole as a Dual-Targeted Radiosensitizer for Osteosarcoma: Targeting Tumor Ce...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32040174/" target="_blank">32040174</a></td><td>2020</td><td>Article</td><td>Toxicological sciences : an of</td><td>Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31108504/" target="_blank">31108504</a></td><td>2019</td><td>Article</td><td>Human molecular genetics</td><td>Altered calcium dynamics and glutamate receptor properties in iPSC-derived motor...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8061281/" target="_blank">8061281</a></td><td>1994</td><td>Article</td><td>Neuroreport</td><td>Neuroprotective effects of riluzole in ALS CSF toxicity.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. autosomal dominant mitochondrial myopathy with exercise intolerance</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. amyotrohpic lateral sclerosis type 22</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬XXXXXXè™Ÿ | ç‰¹é­¯å¸Œå£æœæ‡¸æµ®æ¶² 5æ¯«å…‹/æ¯«å‡ | å£æœæ‡¸æµ®æ¶² | è‚Œèç¸®è„Šé«“å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- è‚æ¯’æ€§ï¼šéœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
- é–“è³ªæ€§è‚ºç—…ï¼šç½•è¦‹ä½†åš´é‡

**ç¦å¿Œç—‡ï¼š**
- åš´é‡è‚åŠŸèƒ½æå®³

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**å’–å•¡å› ï¼ˆå’–å•¡ã€èŒ¶ã€å¯æ¨‚ï¼‰** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šå’–å•¡å› å¯èƒ½èˆ‡ Riluzole ç«¶çˆ­ä»£è¬
- å»ºè­°ï¼šé©é‡æ”å–å’–å•¡å› 


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Alcoholism** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šAlcohol consumption may intensify the hepatotoxic potential of riluzole...

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Neutropenia** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šThe use of riluzole has rarely been associated with neutropenia with an absolute neutrophil count (ANC) less than 500/mm3...

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šè€å¹´äººã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
TxGNN é æ¸¬çš„é©æ‡‰ç—‡èˆ‡ ALS åœ¨ç—…ç†æ©Ÿè½‰ä¸Šé«˜åº¦ç›¸é—œï¼Œéƒ½æ¶‰åŠé‹å‹•ç¥ç¶“å…ƒçš„é€€åŒ–ã€‚Riluzole çš„ç¥ç¶“ä¿è­·ä½œç”¨æ©Ÿè½‰ï¼ˆæŠ—è°·æ°¨é…¸æ¯’æ€§ï¼‰åœ¨ç†è«–ä¸Šå¯èƒ½å°é€™äº›ç–¾ç—…æœ‰æ•ˆã€‚ç„¶è€Œï¼Œç”±æ–¼ç¼ºä¹é‡å°é€™äº›ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—æ•¸æ“šï¼Œéœ€è¦è¬¹æ…è©•ä¼°ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å° Mills ç—‡å€™ç¾¤ã€å–®è‚¢è‚Œèç¸®ç—‡ç­‰é‹å‹•ç¥ç¶“å…ƒç–¾ç—…é€²è¡Œå°è¦æ¨¡è‡¨åºŠç ”ç©¶
- æ”¶é›†çœŸå¯¦ä¸–ç•Œè­‰æ“šï¼ˆå¦‚ ALS é–€è¨ºä¸­å…¶ä»–é‹å‹•ç¥ç¶“å…ƒç–¾ç—…æ‚£è€…ä½¿ç”¨ riluzole çš„ç¶“é©—ï¼‰
- å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
- è©•ä¼°é•·æœŸç™‚æ•ˆå’Œå®‰å…¨æ€§

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cisatracurium]({{ "/drugs/cisatracurium/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Minoxidil]({{ "/drugs/minoxidil/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Dl-Alpha-Tocopherol]({{ "/drugs/dl-alpha-tocopherol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Acebutolol]({{ "/drugs/acebutolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Riluzoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/riluzole/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_riluzole,
  title = {Riluzoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/riluzole/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
